Niemann-Pick Disease: How Types A, B, and C Differ

Niemann-Pick disease is a group of inherited disorders in which lipids accumulate inside cells because the body cannot properly break them down or move them where they need to go. Despite sharing a name, the conditions under this umbrella involve different genes, different mechanisms, and dramatically different outlooks. Two main categories exist: acid sphingomyelinase deficiency, which causes types A and B, and a cholesterol-trafficking defect responsible for type C. All forms are rare, all are autosomal recessive, and all can affect the liver, spleen, lungs, and brain to varying degrees.

Two Distinct Metabolic Problems Under One Name

The label “Niemann-Pick disease” dates to the early twentieth century, when clinicians grouped patients together based on overlapping features like enlarged livers and spleens and the presence of lipid-laden foam cells in tissue samples. It took decades of biochemical work to show that these patients actually had two separate metabolic problems.

Types A and B are caused by mutations in the SMPD1 gene, which provides instructions for making an enzyme called acid sphingomyelinase. When that enzyme does not work, a fatty substance called sphingomyelin builds up in cells throughout the body, especially in the liver, spleen, and lungs.¹ The mutant enzyme proteins are actually produced and delivered to lysosomes in normal amounts; they just cannot do their job once they get there.²

Type C is a different story. It results from mutations in either the NPC1 or NPC2 gene, both of which encode proteins needed for moving cholesterol out of lysosomes. When either protein is missing or broken, unesterified cholesterol gets trapped inside the lysosomal compartment of every cell.³ The NPC1 and NPC2 proteins normally work together in a hand-off system: NPC2 binds cholesterol inside the lysosome and passes it to NPC1, which sits in the lysosomal membrane and ferries cholesterol out to the rest of the cell.⁴ When that relay fails, cholesterol piles up along with other lipids called glycosphingolipids, triggering progressive organ and brain damage.

Type A: Severe Infantile Disease

Type A is the most devastating form. Infants appear healthy at birth and develop normally for a few months. The first sign is almost always an enlarged liver and spleen. Developmental progress stalls before the first birthday: affected children do not advance beyond roughly nine to twelve months of developmental age across motor, language, and adaptive skills. Cherry-red spots on the retina appear by twelve months in essentially all cases. As the disease progresses, children develop worsening muscle weakness, lose reflexes, and become increasingly irritable. Frequent vomiting, failure to thrive, and recurrent lung infections are common. Death typically results from respiratory failure, and most children do not survive beyond two to three years of age.⁵

Type B: Visceral Disease Without the Brain Involvement

Type B involves the same enzyme deficiency as type A but with enough residual enzyme activity to spare the central nervous system. People with type B also develop hepatosplenomegaly and significant lung disease, but they lack the neurological decline that defines type A. Most patients survive into adulthood.⁶ Pulmonary involvement is particularly prominent in type B, often presenting as interstitial lung disease with reduced oxygen-diffusing capacity. Sphingomyelin accumulates most heavily in the liver, spleen, and lungs, and foam cells can be found on biopsy in those organs.⁷ Some patients also develop unfavorable blood lipid profiles. There is a clinical spectrum between types A and B, and patients with intermediate severity do exist, which is why the umbrella term “acid sphingomyelinase deficiency” (ASMD) is now preferred.

Type C: A Cholesterol Trafficking Disorder

Type C has the widest age range of any form. Some cases present in the fetal or neonatal period, while others do not become apparent until adulthood, when patients develop progressive cognitive decline or psychiatric symptoms. In children, the disease often shows up first as clumsiness and difficulty walking, driven by cerebellar dysfunction. Vertical gaze palsy, an inability to look up or down voluntarily, is one of the hallmark early neurological signs. Seizures and progressive cognitive decline follow. A distinctive and sometimes overlooked feature is gelastic cataplexy: sudden episodes of muscle weakness triggered by laughter or strong emotion. In at least some cases, recognizing these “drop attacks” on laughing has been the clue that pointed clinicians toward the correct diagnosis.⁸

Phenotypes range enormously depending on which NPC1 or NPC2 mutation a person carries and when symptoms begin. As a general rule, earlier onset correlates with faster progression and shorter survival, while adolescent or adult-onset cases may progress over decades.⁹

What Happens in the Brain

The nervous system damage in Niemann-Pick disease, whether type A or type C, follows a pattern. In type C, the cerebellum’s Purkinje cells are especially vulnerable. These large neurons are essential for coordinating movement, and their loss is what produces the cerebellar ataxia, the unsteady gait and poor coordination, that characterizes the disease.¹⁰

Research in mouse models has shed light on why Purkinje cells die before other neurons. Abnormal activation of microglia, the brain’s immune cells, appears to precede Purkinje cell death. In the cerebellar molecular layer, microglia become reactive early, and increasing interactions between microglia and Purkinje cells seem to contribute to their destruction. Gangliosides and cholesterol also accumulate abnormally in neurons.¹¹ Beyond direct lipid toxicity, cells with NPC1 deficiency also have trouble with autophagy, the routine housekeeping process that clears out damaged components. Autophagosomes form but fail to mature properly because the internal membrane machinery that fuses them with other compartments does not work correctly.¹² This backup likely compounds the damage caused by lipid accumulation alone.

Diagnosis and Biomarkers

Diagnosing Niemann-Pick disease has historically been slow. For types A and B, measuring acid sphingomyelinase activity in white blood cells or cultured skin cells, followed by genetic sequencing of SMPD1, is the standard approach. Type C is trickier because the enzyme involved is not a simple single-step reaction you can measure in a blood test. For decades, the gold-standard diagnostic for type C was the filipin staining test, which visualizes cholesterol accumulation in cultured skin fibroblasts. The test works but takes weeks and requires a skin biopsy.

More recently, blood-based biomarkers have transformed type C diagnostics. Three disease-specific molecules, cholestane-triol, trihydroxycholanic acid glycinate, and a phospholipid initially called lysoSM-509, can now be measured from a simple blood draw, making screening far more practical.¹³ These biomarkers are not yet part of routine newborn screening panels in most countries, though pilot studies have explored using dried blood spots to detect bile acid metabolites associated with NPC1 in neonates.

Clinicians tracking disease progression now use standardized severity scales. An international consensus recommends a 17-domain clinical severity scale for research trials and a streamlined 5-domain version for routine clinical visits. The five core domains, walking ability, swallowing, cognition, speech, and fine motor skills, were identified as most important by clinicians, caregivers, and patients alike.¹⁴ Even a one-point change on this abbreviated scale is considered meaningful by patients and families.¹⁵

Who Is at Higher Risk

All forms of Niemann-Pick disease are autosomal recessive, meaning a child must inherit a faulty gene copy from each parent. Carrier parents are usually completely healthy. Type A has a well-documented elevated frequency among people of Ashkenazi Jewish descent. Three specific SMPD1 mutations account for the vast majority of type A chromosomes in that population, and carrier screening puts the carrier frequency at about 1 in 90.¹⁶ One of these mutations, called R496L, was found in about a third of Ashkenazi Jewish type A alleles studied but was far less common in non-Jewish patients.¹⁷ Carrier screening for these mutations is now commonly offered alongside testing for Tay-Sachs and other conditions during preconception genetic panels for Ashkenazi Jewish couples.

Type C does not cluster as strongly in any single ethnic group, though certain mutations are more common in specific populations. The disease occurs worldwide and affects all ethnic backgrounds.

Enzyme Replacement Therapy for ASMD

For types A and B, which share the same enzyme deficiency, the major recent advance is olipudase alfa, a recombinant form of acid sphingomyelinase given by intravenous infusion. It is approved for the non-brain manifestations of ASMD in children and adults. A systematic review of clinical trials found that after two years of treatment, patients saw their spleen volumes drop by roughly half, liver volumes shrink by about a third to nearly 40%, and lung diffusing capacity increase by around 35%.¹⁸ Longer follow-up data extending to six and a half years of continuous treatment showed these improvements were sustained and even deepened over time, with spleen volumes decreasing by about 60% and lung function improving by over 55% from baseline. Patients also experienced lasting improvements in their blood lipid profiles.¹⁹

A critical limitation is that olipudase alfa does not cross the blood-brain barrier in meaningful amounts. For type B, where brain involvement is absent or minimal, this is less of a problem. For type A, where severe neurological disease dominates, enzyme replacement addresses the organ enlargement but cannot halt the neurodegeneration. This remains one of the central unsolved challenges in the field.

Managing Type C With Miglustat

Type C requires a completely different therapeutic strategy because the problem is cholesterol trafficking, not enzyme deficiency. The most widely used treatment is miglustat, a small molecule that works by inhibiting an enzyme involved in the first step of glycosphingolipid synthesis. By reducing the production of these lipids rather than trying to clear them after they have accumulated, miglustat acts as a form of substrate reduction therapy.²⁰

Miglustat does not cure the disease, but data from a large international registry showed that about 70% of patients on continuous miglustat therapy had stable or improved disease across at least three of four tracked domains over the follow-up period.²¹ The drug is taken orally, which is a practical advantage over infused therapies. Side effects include gastrointestinal issues, especially diarrhea, and some patients experience tremor or peripheral neuropathy. Miglustat is approved for type C in many countries but not the United States, where it has only an FDA approval for a different condition (Gaucher disease type 1).

Cyclodextrin and the Promise of Freeing Trapped Cholesterol

One of the more unconventional therapeutic avenues for type C involves cyclodextrin, a ring-shaped sugar molecule traditionally used as a pharmaceutical excipient. Researchers discovered that 2-hydroxypropyl-β-cyclodextrin (HPβCD) could dramatically reduce cholesterol accumulation in cells and in mouse models of the disease. In mice, systemic administration of HPβCD reduced lysosomal cholesterol storage in nearly every organ, slowed neurodegeneration, and significantly extended lifespan.²²

The mechanism turns out to be surprisingly specific. Rather than simply stripping cholesterol from cell membranes, cyclodextrin is taken up into cells through endocytosis and works from inside the endocytic compartments, directly helping cholesterol escape the lysosomal trap. Treated cells show a burst of cholesterol esterification by an enzyme in the endoplasmic reticulum, a sign that cholesterol is being successfully delivered out of the lysosome to other parts of the cell.²³ The cholesterol transport block caused by NPC1 or NPC2 deficiency is effectively bypassed.²⁴ Clinical trials of HPβCD in human patients have been ongoing, though getting enough of it into the brain remains a challenge because large sugar molecules do not easily cross the blood-brain barrier.

Gene Therapy and Combination Approaches

Gene therapy represents the most ambitious strategy for type C. The idea is straightforward: deliver a working copy of the NPC1 gene directly to the brain. In practice, the large size of the NPC1 gene makes packaging it into adeno-associated virus (AAV) vectors difficult. Researchers have addressed this by engineering smaller promoter sequences that still drive strong gene expression. In one study, a novel truncated NPC1 promoter paired with an AAV9 vector was injected into the brains of newborn NPC mice and outperformed several commonly used promoters, extending survival and reducing neuropathology.²⁵

Separate work using a different AAV vector carrying human NPC1 under a standard promoter showed similarly encouraging results. Treated knockout mice survived an average of beyond 28 weeks, while all untreated mice died within 16 weeks.²⁶ These are mouse data, and translating them to humans involves far larger brain volumes and more complex immune considerations, but the proof of concept is strong.

Some researchers are also exploring combination strategies. A triple formulation combining vorinostat, an HDAC inhibitor that boosts levels of the NPC1 protein, with HPβCD and a stabilizing polymer was tested in NPC mice. Vorinostat alone improved cholesterol handling in cultured cells but did not extend survival in animals. The triple combination, however, increased histone acetylation in the brain, preserved Purkinje cells, and more than doubled lifespan from about four months to nearly nine months.²⁷ The rationale behind including vorinostat is that certain NPC1 mutations produce a protein that could still function if it were stabilized and delivered to the right compartment; HDAC inhibitors appear to increase the amount of mutant NPC1 protein that reaches the lysosome.²⁸ Since vorinostat is already approved for another condition, the possibility of repurposing it has drawn interest, though no human trials specific to NPC have yet reported results with this combination.²⁹

Living With Niemann-Pick Disease

Beyond the biology and the clinical trials, the daily reality of Niemann-Pick disease is grueling for families. A qualitative study capturing patient and caregiver perspectives found that the disease affects not just patients’ daily activities and quality of life but also reshapes caregivers’ entire routines. Caregivers reported constant adjustments to their schedules, significant demands on their mental energy, and ongoing emotional strain as they watched the disease progress.³⁰

Supportive care is multidisciplinary by necessity. Swallowing therapy matters because aspiration pneumonia is a leading cause of complications. Physical therapy helps maintain mobility for as long as possible. Speech therapy addresses progressive dysarthria. As the disease advances, families face difficult decisions about feeding tubes, respiratory support, and end-of-life care. Published nursing reports describe the challenge of coordinating symptom control and discharge planning for a disease where the trajectory is unpredictable and the medical precedent is thin.³¹ Patient advocacy organizations have become important connectors, linking families to clinical trials, specialist centers, and each other in a disease where even experienced physicians may have seen only a handful of cases.